Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Saniona

16.38 SEK

+0.24 %

Less than 1K followers

SANION

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.24 %
-34.08 %
-22.74 %
-25.21 %
+37.65 %
+134.67 %
+158.81 %
-0.83 %
+318.25 %

Saniona is a biotechnology company focused on developing innovative treatments for neurological and psychiatric diseases. The company is researching new therapies that can improve patient outcomes and quality of life. The company operates globally with a primary presence in Europe and North America. Saniona was founded in 2011 and is headquartered in Denmark.

Read more
Market cap
2.26B SEK
Turnover
31.67M SEK
Revenue
434.4M
EBIT %
62.39 %
P/E
7.41
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27.5
2026

General meeting '26

27.5
2026

Interim report Q1'26

27.8
2026

Interim report Q2'26

All
Research
Press releases
ShowingAll content types
Press release3/12/2026, 1:02 PM

BioStock: Saniona enters clinical execution phase following transformational year

Saniona
Press release3/12/2026, 7:00 AM

Meet Saniona at several conferences during the spring

Saniona
Press release3/3/2026, 9:47 AM

Redeye: Saniona (Q4 review): Moving forward nicely

Saniona

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2/26/2026, 7:00 AM

Saniona publishes its year-end report for 2025

Saniona
Press release2/20/2026, 7:00 AM

Invitation to Saniona Q4 & year-end investor call on 26 February 2026

Saniona
Press release12/17/2025, 7:00 AM

Saniona Bolsters Leadership Team to Accelerate Development of Key CNS Programs

Saniona
Press release12/1/2025, 12:21 PM

BioStock: Saniona comments on major advancements during third quarter

Saniona
Press release11/28/2025, 10:44 AM

Redeye: Saniona (Q3 Review) - Gearing up for clinical development

Saniona
Regulatory press release11/27/2025, 7:00 AM

Saniona publishes its interim report for the third quarter of 2025

Saniona
Press release11/20/2025, 7:00 AM

Invitation to Saniona Q3 investor call on 27 November 2025

Saniona
Press release11/19/2025, 7:16 AM

BioStock: Video from Saniona's presentation at BioStock Life Science Summit 2025

Saniona
Press release11/6/2025, 7:00 AM

Saniona AB’s Nomination Committee for the Annual General Meeting 2026

Saniona
Press release9/25/2025, 7:59 AM

Redeye: Saniona - Optionality unlocked

Saniona
Press release9/9/2025, 7:57 AM

BioStock: Saniona comments on their new chapter in epilepsy treatment

Saniona
Regulatory press release9/4/2025, 6:00 AM

Saniona selects SAN2668 as first-in-class clinical candidate for paediatric epilepsy

Saniona
Regulatory press release8/28/2025, 6:00 AM

Saniona publishes its interim report for the second quarter of 2025

Saniona
Press release8/22/2025, 3:30 PM

Invitation to Saniona Q2 investor call on 28 August 2025

Saniona
Press release8/20/2025, 2:08 PM

BioStock: Saniona’s CEO comments on the billion dollar deal

Saniona
Regulatory press release8/20/2025, 11:30 AM

Saniona Enters Exclusive Licensing Agreement with Jazz Pharmaceuticals to Develop and Commercialize SAN2355

Saniona
Press release8/12/2025, 6:00 AM

Saniona to present at several conferences in the second half of 2025

Saniona
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.